Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving antigen-antibody binding – specific binding protein...
Reexamination Certificate
2011-01-11
2011-01-11
Hobbs, Lisa J (Department: 1657)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving antigen-antibody binding, specific binding protein...
C435S006120
Reexamination Certificate
active
07867727
ABSTRACT:
Disclosed are screening methods for determining a human subject's propensity to develop a vascular disorder and/or age-related macular degeneration (AMD), therapeutic or prophylactic compounds for treating disease or inhibiting its development, and methods of treating patients to alleviate symptoms of the disease, prevent or delay its onset, or inhibit its progression. The inventions are based on the discovery that persons with a genome having a deletion of the CFHR-1 and/or CFHR-3 gene, which normally lie on human chromosome 1 between DNA encoding CFH and CFHR-4, are at reduced risk of developing AMD, and elevated risk of developing vascular disease such as aneurysm.
REFERENCES:
patent: 5474796 (1995-12-01), Brennan
patent: 2002/0015957 (2002-02-01), Hageman et al.
patent: 2004/0170633 (2004-09-01), Taylor et al.
patent: 2008/0146501 (2008-06-01), Hageman et al.
patent: 2008/0261211 (2008-10-01), Allikmets et al.
patent: 2008/0280825 (2008-11-01), Hageman et al.
patent: 2009/0017029 (2009-01-01), Hoh et al.
patent: 2009/0312394 (2009-12-01), Hughes
patent: WO 2007/056111 (2007-05-01), None
patent: WO 2007/144621 (2007-12-01), None
Abrera-Abeleda, M.A., et al., “Variations in the complement regulatory genes factor H (CFH) and factor H related 5 (CFHR5) are associated with membranoproliferative glomerulonephritis type II (dense deposit disease),”J. Med. Genet, 43:582-589, 2006, E-Publication Nov. 18, 2005.
Boerhinger Mannheim, “Non-Radioactive Labeling and Detection of Nucleric Acids,”1997 Biochemical Catalog, cover page and p. 65.
Despriet, D., et al, “Complement Factor H Polymorphism Complement Activators, and Risk of Age-Related Macular Degeneration,”JAMA, Jul. 19, 2006 vol. 296, pp. 301-309.
Dragon-Durey, M., et al., Heterozygous and Homozygous Factor H Deficiencies Associated with Hemolytic Uremic Syndrome or Membranoproliferative Glomerulonephritis: Report and Genetic Analysis of 16 Cases,J Am Soc Nephrol. (2004) 15:787-795.
Edwards et al., “Complement Factor H Polymorphism in Age-Relaged Macular Degeneration,”Science, 308:421-424, Apr. 15, 2005.
Francis, Peter J., “Haplotypes in the Complement Factor H (CFH) Gene: Associations with Drusen and Advanced Age-Related Macular Degeneration,”PloS One, 2007 vol. 2, pp. 1-6.
Gotoh, N. et al., “No association between complement factor H gene polymorphism and exudative age-related macular degeneration in Japanese,”Human Genetics, 2006, 120:139-143.
Hageman et al., “A common haplotype in the complement regulatory gene factor H (HF1/CFH) predisposes individuals to age-related macular degeneration,”PNAS, 102:20: 7227-7232, May 17, 2005.
Haines et al, “Complement Factor H Variant Increases the Risk of Age-Related Macular Degeneration,”Science, 308:419-421, Apr. 15, 2005.
Hughes, Anne E., et al, “A common CFH haplotype of CFHR1 and CFHR3, is associated with the lower risk of age-related macular degeneration,”Nature Genetics, Oct. 2006 (E publication Sep. 24, 2006), vol. 38, pp. 1173-1178.
PCT Search Report for application No. PCT/US07/73514 of Aug. 13, 2008.
Written Opinion for application No. PCT/US07/73514 of Aug. 13, 2008.
EP 07812932.7 European Supplementary Search Report completed Sep. 16, 2009.
Heinen et al, “De Novo Gene Conversion in the RCA Gene Cluster (1q32) Causes Mutations in Complement Factor H Associated with Atypical Hemolytic Uremic Syndrome,”Human Mutation, 27(3):292-293 (2006).
Perez-Caballero et al., “Clustering of Missense Mutations in the C-Terminal Region of Factor H in Atypical Hemolytic Uremic Syndrome,”American Journal of Human Genetics, 68(2):478-484 (2001).
Klein et al., “Complement Factor H Polymorphism in Age-Related Macular Degeneration,”Science, 308:385-389, Apr. 15, 2005.
Li, M. et al., “CFH haplotypes without the Y402H coding variant show strong association with susceptibility to age-related macular degeneration,”Nature Genetics, Sep. 2006, vol. 38, No. 9, pp. 1049-1054.
Magnusson, K. P., et al., “CFH Y402H Confers Similar Risk of Soft Drusen and Both Forms of Advanced AMD,”PLoS Medicine, vol. 3, Issue e5, pp. 109-113.
Mullins, R., et al., “Structure and composition of drusen associated with glomerulonephritis: Implications for the role of complement activation in drusen biogenesis”,Eye(2001) 15:390-395.
Nicaud, V. et al., “Lack of association between complement factor H polymorphisms and coronary artery disease or myocardial infarction,”Journal of Molecular Medicine, 2007, 85:771-775.
Reference SNP Cluster Report: rs641153 available at http://www.ncbi.nlm.nih.gov/projects/SNP.
Tedeschi-Blok, N. et al., “Population-Based Study of Early Age-Related Macular Degeneration, Role of the Complement Factor H Y402H Polymorphism in Bilateral but Not Unilateral Disease,”Ophthalmology, Jan. 2007, 114:99-103.
PCT Search Report for application No. PCT/US07/03696 of Jun. 12, 2008.
Written Opinion for application No. PCT/US07/03696 of Jun. 12, 2008.
PCT Search Report for application No. PCT/US07/03904 of Aug. 1, 2008.
Written Opinion for application No. application PCT/US07/03904 of Aug. 1, 2008.
Hobbs Lisa J
Townsend and Townsend / and Crew LLP
University of Iowa Research Foundation
LandOfFree
Methods and reagents for treatment and diagnosis of vascular... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods and reagents for treatment and diagnosis of vascular..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods and reagents for treatment and diagnosis of vascular... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2676447